Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon Cancer

Journal of the American College of Surgeons

Volumn 208, Issue 2, 2009, Pages 202-209

  Krzyzanowska, Monika K ^a,b   Regan, Meredith M ^c,d   Powell, Mark ^c   Earle, Craig C ^c,d   Weeks, Jane C ^c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; COLON CANCER; COMORBIDITY; ELDERLY CARE; EVALUATION; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; PATIENT REFERRAL; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURGEON; UNITED STATES; VIGNETTE;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMORBIDITY; FEMALE; GENERAL SURGERY; HUMANS; LINEAR MODELS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 58249101411     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.10.016     Document Type: Article

References (31)

1. Edwards B.K., Howe H.L., Ries L.A., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 94 (2002) 2766-2792
2. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264 (1990) 1444-1450
3. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 352-358
4. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122 (1995) 321-326
5. O'Connell M.J., Mailliard J.A., Kahn M.J., et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15 (1997) 246-250
6. Schrag D., Cramer L.D., Bach P.B., and Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93 (2001) 850-857
7. Mahoney T., Kuo Y.H., Topilow A., and Davis J.M. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135 (2000) 182-185
8. Sundararajan V., Grann V.R., Jacobson J.S., et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 7 (2001) 213-218
9. Potosky A.L., Harlan L.C., Kaplan R.S., et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20 (2002) 1192-1202
10. Jessup J.M., Stewart A., Greene F.L., and Minsky B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294 (2005) 2703-2711
11. Sargent D.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345 (2001) 1091-1097
12. Iwashyna T.J., and Lamont E.B. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20 (2002) 3992-3998
13. Sundararajan V., Mitra N., Jacobson J.S., et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136 (2002) 349-357
14. Stein B.N., Petrelli N.J., Douglass H.O., et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75 (1995) 11-17
15. Zalcberg J., Kerr D., Seymour L., and Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 34 (1998) 1871-1875
16. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 16 (1998) 3537-3541
17. Haller D.G., Catalano P.J., Macdonald J.S., et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23 (2005) 8671-8678
18. Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15 (2004) 1330-1338
19. Newcomb P.A., and Carbone P.P. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 85 (1993) 1580-1584
20. Liang W., Burnett C.B., Rowland J.H., et al. Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol 20 (2002) 1008-1016
21. Friedmann P.D., Brett A.S., and Mayo-Smith M.F. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 124 (1996) 414-421
22. Potosky A.L., Riley G.F., Lubitz J.D., et al. Potential for cancer related health services research using a linked Medicare-tumorregistry database. Med Care 31 (1993) 732-748
23. In: Rossi P.H., and Nock S.L. (Eds). Measuring social judgements: the factorial survey approach (1982), Sage Publications, Beverly Hills, CA
24. Kellerman S.E., and Herold J. Physician response to surveys. A review of the literature. Am J Prev Med 20 (2001) 61-67
25. Hodgson D.C., Fuchs C.S., and Ayanian J.Z. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93 (2001) 501-515
26. Ayanian J.Z., Zaslavsky A.M., Fuchs C.S., et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 21 (2003) 1293-1300
27. Keating N.L., Landrum M.B., Klabunde C.N., et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?. J Clin Oncol 26 (2008) 2532-2537
28. Gross C.P., McAvay G.J., Krumholz H.M., et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145 (2006) 646-653
29. Gross C.P., McAvay G.J., Guo Z., and Tinetti M.E. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 109 (2007) 2410-2419
30. Luo R., Giordano S.H., Zhang D.D., et al. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer 109 (2007) 975-982
31. Mandelblatt J.S., Berg C.D., Meropol N.J., et al. Measuring and predicting surgeons' practice styles for breast cancer treatment in older women. Med Care 39 (2001) 228-242